X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SHASUN PHARMA ALKEM LABORATORIES/
SHASUN PHARMA
 
P/E (TTM) x - 123.9 - View Chart
P/BV x 6.9 8.5 81.4% View Chart
Dividend Yield % 0.6 0.2 267.8%  

Financials

 ALKEM LABORATORIES   SHASUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SHASUN PHARMA
Mar-14
ALKEM LABORATORIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,58994 1,686.8%   
Low Rs1,23246 2,701.8%   
Sales per share (Unadj.) Rs417.5214.2 194.9%  
Earnings per share (Unadj.) Rs56.35.3 1,055.0%  
Cash flow per share (Unadj.) Rs64.715.8 409.0%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.91.4 62.9%  
Book value per share (Unadj.) Rs292.953.3 549.2%  
Shares outstanding (eoy) m119.5756.62 211.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,035.3%   
Avg P/E ratio x25.113.1 191.3%  
P/CF ratio (eoy) x21.84.4 493.3%  
Price / Book Value ratio x4.81.3 367.4%  
Dividend payout %22.618.7 120.4%   
Avg Mkt Cap Rs m168,6533,958 4,261.4%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1712,164 423.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91512,127 411.6%  
Other income Rs m1,645229 717.3%   
Total revenues Rs m51,56112,356 417.3%   
Gross profit Rs m8,4821,009 840.6%  
Depreciation Rs m1,006594 169.4%   
Interest Rs m671415 161.6%   
Profit before tax Rs m8,451230 3,679.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606-73 -2,208.5%   
Profit after tax Rs m6,731302 2,228.0%  
Gross profit margin %17.08.3 204.2%  
Effective tax rate %19.0-31.7 -60.0%   
Net profit margin %13.52.5 541.3%  
BALANCE SHEET DATA
Current assets Rs m27,0626,884 393.1%   
Current liabilities Rs m15,3248,456 181.2%   
Net working cap to sales %23.5-13.0 -181.5%  
Current ratio x1.80.8 216.9%  
Inventory Days Days6762 107.9%  
Debtors Days Days41108 38.4%  
Net fixed assets Rs m12,6104,970 253.7%   
Share capital Rs m239113 211.0%   
"Free" reserves Rs m34,4902,875 1,199.7%   
Net worth Rs m35,0273,020 1,159.7%   
Long term debt Rs m1,2121,817 66.7%   
Total assets Rs m54,38713,347 407.5%  
Interest coverage x13.61.6 875.7%   
Debt to equity ratio x00.6 5.7%  
Sales to assets ratio x0.90.9 101.0%   
Return on assets %13.65.4 253.3%  
Return on equity %19.210.0 192.1%  
Return on capital %24.913.3 186.6%  
Exports to sales %12.946.4 27.9%   
Imports to sales %3.114.2 21.7%   
Exports (fob) Rs m6,4615,622 114.9%   
Imports (cif) Rs m1,5401,728 89.2%   
Fx inflow Rs m6,5635,843 112.3%   
Fx outflow Rs m3,0122,173 138.6%   
Net fx Rs m3,5523,669 96.8%   
CASH FLOW
From Operations Rs m7,259398 1,825.6%  
From Investments Rs m1,864-1,635 -114.0%  
From Financial Activity Rs m-9,2731,309 -708.6%  
Net Cashflow Rs m-15071 -210.7%  

Share Holding

Indian Promoters % 66.9 39.2 170.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 3.6 919.4%  
FIIs % 0.0 17.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 39.6 -  
Shareholders   68,381 20,750 329.5%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 24, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS